Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$52.37+1.8%$51.48$35.45▼$61.69$105.86B0.354.60 million shs496,661 shsMRKMerck & Co., Inc.$127.02+2.8%$119.48$76.66▼$130.29$313.22B0.1910.93 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+0.33%-2.12%-1.50%-9.96%+36.05%MRKMerck & Co., Inc.+2.19%-2.02%+7.41%+7.05%+51.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$52.37+1.8%$51.48$35.45▼$61.69$105.86B0.354.60 million shs496,661 shsMRKMerck & Co., Inc.$127.02+2.8%$119.48$76.66▼$130.29$313.22B0.1910.93 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+0.33%-2.12%-1.50%-9.96%+36.05%MRKMerck & Co., Inc.+2.19%-2.02%+7.41%+7.05%+51.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 2.10Hold$53.001.20% UpsideMRKMerck & Co., Inc. 2.70Moderate Buy$133.945.45% UpsideCurrent Analyst Ratings BreakdownLatest MRK and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $140.007/13/2026MRKMerck & Co., Inc. BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$135.00 ➝ $142.007/13/2026MRKMerck & Co., Inc. GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $145.007/9/2026GSKGSK Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/9/2026MRKMerck & Co., Inc. Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$112.00 ➝ $113.007/8/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.007/8/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$145.00 ➝ $150.007/6/2026GSKGSK HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Hold7/6/2026MRKMerck & Co., Inc. Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$120.006/30/2026MRKMerck & Co., Inc. Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $141.006/30/2026MRKMerck & Co., Inc. ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$136.00 ➝ $155.00(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$43.07B2.46$6.14 per share8.53$10.32 per share5.08MRKMerck & Co., Inc.$65.01B4.83$12.02 per share10.57$21.22 per share5.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$7.54B$3.8513.6010.413.2917.82%44.28%11.49%7/28/2026 (Estimated)MRKMerck & Co., Inc.$18.25B$3.5535.7212.903.0313.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MRKMerck & Co., Inc.$1.36N/AN/AN/A$16.39 billionN/A7/28/2026Q2 2026GSKGSK$1.27N/AN/AN/A$11.02 billionN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.793.42%-7.86%46.49%N/AMRKMerck & Co., Inc.$3.402.68%+5.75%95.77%14 YearsLatest MRK and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20265/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK0.800.790.52MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK66,8412.02 billion1.82 billionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK and GSK HeadlinesRecent News About These CompaniesMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia2 hours ago | finance.yahoo.comMerck Gets Approval for Powerful Cholesterol-Cutting Pill2 hours ago | finance.yahoo.comMerck Gets Approval for Powerful Cholesterol-Cutting Pill3 hours ago | barrons.comMerck's cholesterol pill gets US FDA approval3 hours ago | reuters.comMerck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia3 hours ago | businesswire.comThe FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve3 hours ago | wsj.comWealthfront Advisers LLC Has $37.44 Million Holdings in Merck & Co., Inc. $MRK4 hours ago | marketbeat.comNavigation Group LLC Invests $1.24 Million in Merck & Co., Inc. $MRK4 hours ago | marketbeat.comTwin Capital Management Inc. Has $4.80 Million Stock Holdings in Merck & Co., Inc. $MRK4 hours ago | marketbeat.comIllinois Municipal Retirement Fund Trims Stock Holdings in Merck & Co., Inc. $MRK4 hours ago | marketbeat.comBank of New York Mellon Corp Has $2.25 Billion Holdings in Merck & Co., Inc. $MRKJuly 16 at 3:11 AM | marketbeat.comMerck (MRK) Wins FDA Nod For New Keytruda Bladder Cancer UseJuly 15 at 1:03 PM | finance.yahoo.comMerck posts late-stage trial win for frontline Keytruda in endometrial cancerJuly 15 at 1:03 PM | seekingalpha.comCan Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer?July 15 at 1:03 PM | finance.yahoo.comKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to ChemotherapyJuly 15 at 8:02 AM | finance.yahoo.comMerck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026July 15 at 8:02 AM | finance.yahoo.comSanctuary Advisors LLC Purchases 48,579 Shares of Merck & Co., Inc. $MRKJuly 15 at 6:07 AM | marketbeat.comEarnings preview: What to expect from Merck & Co.'s reportJuly 14 at 11:59 AM | msn.comCan BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?July 14 at 11:59 AM | finance.yahoo.comHere's How Pfizer's Oncology Growth Story Looks Ahead of Q2 ResultsJuly 14 at 11:59 AM | finance.yahoo.comHCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of LossesJuly 14 at 11:59 AM | stocktwits.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and GSK Company DescriptionsGSK NYSE:GSK$52.37 +0.92 (+1.80%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Merck & Co., Inc. NYSE:MRK$127.02 +3.41 (+2.76%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Which Storage Stock Is Best Positioned to Win the AI Memory War? Cintas Keeps Beating Expectations—And the Story Isn’t Over Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
